共 50 条
- [32] Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents CLINICAL AND EXPERIMENTAL ALLERGY, 2019, 49 (10): : 1328 - 1341
- [33] Peanut oral immunotherapy protects patients from accidental allergic reactions to peanut JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (07): : 2437 - +
- [35] CHANGES IN PEANUT COMPONENT SIGE AND SIGG4 ASSOCIATED WITH PROBIOTIC AND PEANUT ORAL IMMUNOTHERAPY (PPOIT) IN PEANUT ALLERGIC CHILDREN: PERSISTENT CHALLENGE-PROVEN SUSTAINED UNRESPONSIVENESS (SU) IS ASSOCIATED WITH REDUCED ARAH 1, 2, 3 SIGE BUT NOT ELEVATED SIGG4 INTERNAL MEDICINE JOURNAL, 2017, 47 : 16 - 17
- [37] Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children CLINICAL AND EXPERIMENTAL ALLERGY, 2012, 42 (08): : 1197 - 1205